Zai Lab and Pfizer have entered a strategic collaboration to commercialise XACDURO (sulbactam-durlobactam), a new ...

For those looking for great candidates, here are two in the healthcare sector: Merck ( MRK 2.48%) and Pfizer ( PFE 0.76%).

The plant is a key producer of sterile injectables, responsible for manufacturing nearly 25% of all Pfizer sterile injectable ...

Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for ...

Meanwhile, Pfizer's forward earnings multiple is only 8.3. This stark contrast stems from the companies' growth prospects.

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics ...

Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to ...

We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a ...

Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...

Recently, Pfizer has launched a specialised centre at a hospital in Gurugram and is planning to start more such centres to ...

A woman sued Pfizer, alleging the birth control shot Depo-Provera caused her brain tumors, following a study linking the drug ...

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...